Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2α.

Kroeger N, Seligson DB, Signoretti S, Yu H, Magyar CE, Huang J, Belldegrun AS, Pantuck AJ.

Eur J Cancer. 2014 May;50(8):1531-40. doi: 10.1016/j.ejca.2014.01.031. Epub 2014 Feb 21.

PMID:
24565854
2.

Histone acetylation regulates intracellular pH.

McBrian MA, Behbahan IS, Ferrari R, Su T, Huang TW, Li K, Hong CS, Christofk HR, Vogelauer M, Seligson DB, Kurdistani SK.

Mol Cell. 2013 Jan 24;49(2):310-21. doi: 10.1016/j.molcel.2012.10.025. Epub 2012 Nov 29.

3.

IGFBP-3 nuclear localization predicts human prostate cancer recurrence.

Seligson DB, Yu H, Tze S, Said J, Pantuck AJ, Cohen P, Lee KW.

Horm Cancer. 2013 Feb;4(1):12-23. doi: 10.1007/s12672-012-0124-8. Epub 2012 Sep 26.

4.

Expression of thyroid transcription factor-1 in normal endometrium is associated with risk of endometrial cancer development.

Sullivan PS, Maresh EL, Seligson DB, Habeeb O, Wadehra M, Goodglick L, Dorigo O.

Mod Pathol. 2012 Aug;25(8):1140-8. doi: 10.1038/modpathol.2012.64. Epub 2012 Mar 30.

5.

Clinical, molecular, and genetic correlates of lymphatic spread in clear cell renal cell carcinoma.

Kroeger N, Seligson DB, Klatte T, Rampersaud EN, Birkhäuser FD, Rao PN, Leppert JT, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Eur Urol. 2012 May;61(5):888-95. doi: 10.1016/j.eururo.2012.01.012. Epub 2012 Jan 18.

PMID:
22269604
6.

Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival.

Kroeger N, Klatte T, Birkhäuser FD, Rampersaud EN, Seligson DB, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

Cancer. 2012 Apr 1;118(7):1795-802. doi: 10.1002/cncr.26453. Epub 2011 Aug 25.

7.

Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features.

Klatte T, Said JW, Seligson DB, Rao PN, de Martino M, Shuch B, Zomorodian N, Kabbinavar FF, Belldegrun AS, Pantuck AJ.

J Urol. 2011 Jan;185(1):30-5. doi: 10.1016/j.juro.2010.09.013. Epub 2010 Nov 12.

PMID:
21074210
8.

Elevated MED28 expression predicts poor outcome in women with breast cancer.

Yoon NK, Maresh EL, Elshimali Y, Li A, Horvath S, Seligson DB, Chia D, Goodglick L.

BMC Cancer. 2010 Jun 28;10:335. doi: 10.1186/1471-2407-10-335.

9.

Epithelial membrane protein-2 expression is an early predictor of endometrial cancer development.

Habeeb O, Goodglick L, Soslow RA, Rao RG, Gordon LK, Schirripa O, Horvath S, Braun J, Seligson DB, Wadehra M.

Cancer. 2010 Oct 15;116(20):4718-26. doi: 10.1002/cncr.25259.

10.

Absent CD44v6 expression is an independent predictor of poor urothelial bladder cancer outcome.

Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Garraway I, Wong SG, Belldegrun AS, Pantuck AJ.

J Urol. 2010 Jun;183(6):2403-8. doi: 10.1016/j.juro.2010.01.064. Epub 2010 Apr 18.

PMID:
20403620
11.

Cellular histone modification patterns predict prognosis and treatment response in resectable pancreatic adenocarcinoma: results from RTOG 9704.

Manuyakorn A, Paulus R, Farrell J, Dawson NA, Tze S, Cheung-Lau G, Hines OJ, Reber H, Seligson DB, Horvath S, Kurdistani SK, Guha C, Dawson DW.

J Clin Oncol. 2010 Mar 10;28(8):1358-65. doi: 10.1200/JCO.2009.24.5639. Epub 2010 Feb 8.

12.

Higher expression levels of 14-3-3sigma in ductal carcinoma in situ of the breast predict poorer outcome.

Yoon NK, Seligson DB, Chia D, Elshimali Y, Sulur G, Li A, Horvath S, Maresh E, Mah V, Bose S, Bonavida B, Goodglick L.

Cancer Biomark. 2009;5(4):215-24. doi: 10.3233/CBM-2009-0106.

13.

CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.

de Martino M, Klatte T, Seligson DB, LaRochelle J, Shuch B, Caliliw R, Li Z, Kabbinavar FF, Pantuck AJ, Belldegrun AS.

J Urol. 2009 Aug;182(2):728-34. doi: 10.1016/j.juro.2009.03.077. Epub 2009 Jun 18.

PMID:
19539328
14.

Global levels of histone modifications predict prognosis in different cancers.

Seligson DB, Horvath S, McBrian MA, Mah V, Yu H, Tze S, Wang Q, Chia D, Goodglick L, Kurdistani SK.

Am J Pathol. 2009 May;174(5):1619-28. doi: 10.2353/ajpath.2009.080874. Epub 2009 Apr 6.

15.

Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.

Klatte T, Seligson DB, LaRochelle J, Shuch B, Said JW, Riggs SB, Zomorodian N, Kabbinavar FF, Pantuck AJ, Belldegrun AS.

Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):894-900. doi: 10.1158/1055-9965.EPI-08-0786. Epub 2009 Feb 24.

16.

Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.

Klatte T, Pantuck AJ, Said JW, Seligson DB, Rao NP, LaRochelle JC, Shuch B, Zisman A, Kabbinavar FF, Belldegrun AS.

Clin Cancer Res. 2009 Feb 15;15(4):1162-9. doi: 10.1158/1078-0432.CCR-08-1229.

17.

Carbonic anhydrase IX in bladder cancer: a diagnostic, prognostic, and therapeutic molecular marker.

Klatte T, Seligson DB, Rao JY, Yu H, de Martino M, Kawaoka K, Wong SG, Belldegrun AS, Pantuck AJ.

Cancer. 2009 Apr 1;115(7):1448-58. doi: 10.1002/cncr.24163.

18.

Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples.

Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, Cavenee WK, Cloughesy TF, Mischel PS.

Clin Cancer Res. 2008 Jan 15;14(2):488-93. doi: 10.1158/1078-0432.CCR-07-1966.

19.

Expression of arginase II in prostate cancer.

Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, Seligson DB, Grody WW.

Int J Oncol. 2008 Feb;32(2):357-65.

PMID:
18202758
20.

Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.

Klatte T, Seligson DB, Riggs SB, Leppert JT, Berkman MK, Kleid MD, Yu H, Kabbinavar FF, Pantuck AJ, Belldegrun AS.

Clin Cancer Res. 2007 Dec 15;13(24):7388-93.

21.

Na,K-adenosine triphosphatase alpha1-subunit predicts survival of renal clear cell carcinoma.

Seligson DB, Rajasekaran SA, Yu H, Liu X, Eeva M, Tze S, Ball W Jr, Horvath S, deKernion JB, Rajasekaran AK.

J Urol. 2008 Jan;179(1):338-45. Epub 2007 Nov 19.

PMID:
18006011
22.

The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma.

Klatte T, Seligson DB, Leppert JT, Riggs SB, Yu H, Zomorodian N, Kabbinavar FF, Strieter RM, Belldegrun AS, Pantuck AJ.

J Urol. 2008 Jan;179(1):61-6. Epub 2007 Nov 13.

PMID:
17997430
23.

Aromatase expression predicts survival in women with early-stage non small cell lung cancer.

Mah V, Seligson DB, Li A, Márquez DC, Wistuba II, Elshimali Y, Fishbein MC, Chia D, Pietras RJ, Goodglick L.

Cancer Res. 2007 Nov 1;67(21):10484-90.

24.

Expression of X-linked inhibitor of apoptosis protein is a strong predictor of human prostate cancer recurrence.

Seligson DB, Hongo F, Huerta-Yepez S, Mizutani Y, Miki T, Yu H, Horvath S, Chia D, Goodglick L, Bonavida B.

Clin Cancer Res. 2007 Oct 15;13(20):6056-63.

25.

Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy.

Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O'Toole T, Gibbons J, Belldegrun AS, Figlin RA.

Cancer. 2007 Jun 1;109(11):2257-67.

26.

Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score.

Lam JS, Seligson DB, Yu H, Li A, Eeva M, Pantuck AJ, Zeng G, Horvath S, Belldegrun AS.

BJU Int. 2006 Aug;98(2):445-51.

27.

Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome.

Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, Hedvat C, Braun J, Soslow RA.

Cancer. 2006 Jul 1;107(1):90-8.

28.

The tissue micro-array as a translational research tool for biomarker profiling and validation.

Seligson DB.

Biomarkers. 2005 Nov;10 Suppl 1:S77-82. Review.

PMID:
16298915
29.

Global histone modification patterns predict risk of prostate cancer recurrence.

Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK.

Nature. 2005 Jun 30;435(7046):1262-6.

PMID:
15988529
30.

Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.

Lam JS, Shvarts O, Said JW, Pantuck AJ, Seligson DB, Aldridge ME, Bui MH, Liu X, Horvath S, Figlin RA, Belldegrun AS.

Cancer. 2005 Jun 15;103(12):2517-25.

31.

Statistical methods for analyzing tissue microarray data.

Liu X, Minin V, Huang Y, Seligson DB, Horvath S.

J Biopharm Stat. 2004 Aug;14(3):671-85.

PMID:
15468758
32.

Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma.

Seligson DB, Pantuck AJ, Liu X, Huang Y, Horvath S, Bui MH, Han KR, Correa AJ, Eeva M, Tze S, Belldegrun AS, Figlin RA.

Clin Cancer Res. 2004 Apr 15;10(8):2659-69.

33.

Prostate stem cell antigen expression is associated with gleason score, seminal vesicle invasion and capsular invasion in prostate cancer.

Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said JW, Reiter RE.

J Urol. 2004 Mar;171(3):1117-21.

PMID:
14767283
34.

Analysis of the Na,K-ATPase alpha- and beta-subunit expression profiles of bladder cancer using tissue microarrays.

Espineda C, Seligson DB, James Ball W Jr, Rao J, Palotie A, Horvath S, Huang Y, Shi T, Rajasekaran AK.

Cancer. 2003 Apr 15;97(8):1859-68.

35.

Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer.

Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS.

Prostate. 2003 Apr 1;55(1):71-80.

PMID:
12640663
36.

Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression.

Ide H, Seligson DB, Memarzadeh S, Xin L, Horvath S, Dubey P, Flick MB, Kacinski BM, Palotie A, Witte ON.

Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14404-9. Epub 2002 Oct 15.

37.

Tissue microarrays in the study of non-neoplastic disease of the nervous system.

Goldstine J, Seligson DB, Beizai P, Miyata H, Vinters HV.

J Neuropathol Exp Neurol. 2002 Aug;61(8):653-62. Review.

PMID:
12152780
38.

Lymphomatosis cerebri presenting as a rapidly progressive dementia: clinical, neuroimaging and pathologic findings.

Bakshi R, Mazziotta JC, Mischel PS, Jahan R, Seligson DB, Vinters HV.

Dement Geriatr Cogn Disord. 1999 Mar-Apr;10(2):152-7.

PMID:
10026390

Supplemental Content

Loading ...
Support Center